Gene therapy for adenosine-deaminase-deficient severe combined immunodeficiency

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 3 SPEC.ISS., 2004, Pages 505-516

  Aiuti, Alessandro ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Adenosine deaminase; Gene transfer; Haematopoietic stem cells; Peripheral blood lymphocytes; Primary immunodeficiency; Retroviral vector

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; FIBRONECTIN; FLT3 LIGAND; IMMUNOGLOBULIN; INTERLEUKIN 3; MACROGOL; MYELOABLATIVE AGENT; RECOMBINANT PROTEIN; RETRONECTIN; RETROVIRUS VECTOR; STEM CELL FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE TRANSFUSION; LYMPHOID HYPERPLASIA; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TREATMENT FAILURE; VIRAL GENE DELIVERY SYSTEM;

EID: 7744224083     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.05.012     Document Type: Article

References (57)

1. Parkman R. Gelfand E.W. Rosen F.S. et al. Severe combined immunodeficiency and adenosine deaminase deficiency New England Journal of Medicine 292 1975 714-719
2. Hershfield M.S. Adenosine deaminase deficiency: Clinical expression, molecular basis, and therapy Seminars in Hematology 35 1998 291-298
3. Hirschorn R. Immunodeficiency disease due to deficiency of adenosine deaminase Ochs H. Smith C. & Puck J. (Eds.) Primary Immunodeficiency Diseases 1999 121-139 Oxford University Press, Oxford
4. Richard E. Arredondo-Vega F.X. Santisteban I. et al. The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV. The arg142gln mutation impairs binding to cd26 but does not cause immune deficiency Journal of Experimental Medicine 192 2000 1223-1236
5. Carlucci F. Tabucchi A. Aiuti A. et al. Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency Clinical Chemistry 49 2003 1830-1838
6. Arredondo V.F. Santisteban I. Daniels S. et al. Adenosine deaminase deficiency: Genotype-phenotype correlations based on expressed activity of 29 mutant alleles American Journal of Human Genetics 63 1998 1049-1059
7. Ozsahin H. Arredondo-Vega F.X. Santisteban I. et al. Adenosine deaminase deficiency in adults Blood 89 1997 2849-2855
8. Ratech H. Hirschhorn R. Greco M.A. Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations American Journal Patholology 135 1989 1145-1156
9. Rogers M.H. Lwin R. Fairbanks L. et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency Journal of Pediatrics 139 2001 44-50
10. Antoine C. Muller S. Cant A. et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99 Lancet 361 2003 553-560
11. Hirschhorn R. Roegner M.V. Kuritsky L. et al. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients The Journal of Clinical Investigation 68 1981 1387-1393
12. Ochs H.D. Buckley R.H. Kobayashi R.H. et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency Blood 80 1992 1163-1171
13. Weinberg K. Hershfield M.S. Bastian J. et al. Lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase The Journal of Clinical Investigation 92 1993 596-602
14. Bordignon C. Roncarolo M.G. Therapeutic applications for hematopoietic stem cell gene transfer Nature Immunology 3 2002 318-321
15. Aiuti A. Ficara F. Cattaneo F. et al. Gene therapy for adenosine deaminase deficiency Current Opinion in Allergy and Clinical Immunology 3 2003 461-466
16. Kantoff P. Kohn D. Mitsuya H. et al. Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer Proceedings of National Academy Sciences, USA 83 1986 6563-6567
17. Ferrari G. Rossini S. Giavazzi R. et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency Science 251 1991 1363-1366
18. Ferrari G. Rossini S. Nobili N. et al. Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions Blood 80 1992 1120-1124
19. Hirschhorn R. Yang D.R. Puck J.M. et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency Nature Genetics 13 1996 290-295
20. Arredondo-Vega F.X. Santisteban I. Richard E. et al. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: Decline in revertant T lymphocytes during enzyme replacement therapy Blood 99 2002 1005-1013
21. Blaese M. Anderson F. Culver K. et al. The ADA human gene therapy clinical protocol Human Gene Therapy 1 1990 327-362
22. Bordignon C. Mavilio F. Ferrari G. et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID Human Gene Therapy 4 1993 513-520
23. Bordignon C. Notarangelo L.D. Nobili N. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients Science 270 1995 470-475
24. Blaese R.M. Culver K.W. Miller A.D. et al. Lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years Science 270 1995 475-480
25. Kohn D.B. Weinberg K.I. Nolta J.A. et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency Nature Medicine 1 1995 1017-1023
26. Onodera M. Ariga T. Kawamura N. et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency Blood 91 1998 30-36
27. Kawamura N. Ariga T. Ohtsu M. et al. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: Role of CD8+cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient The Journal of Immunology 163 1999 2256-2261
28. Aiuti A. Vai S. Mortellaro A. et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement Nature Medicine 8 2002 423-425
29. Muul L.M. Tuschong L.M. Soenen S.L. et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: Long-term results of the first clinical gene therapy trial Blood 101 2003 2563-2569
30. Aiuti A. Advances in gene therapy for ADA-deficient SCID Current Opinion in Molecular Therapeutics 4 2002 515-522
31. Hoogerbrugge P.M. van Beusechem V. Fischer A. et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency Gene Therapy 3 1996 179-183
32. Kohn D.B. Hershfield M.S. Carbonaro D. et al. lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+cells in ADA-deficient SCID neonates Nature Medicine 4 1998 775-780
33. Schmidt M. Carbonaro D.A. Speckmann C. et al. Clonality analysis after retroviral-mediated gene transfer to CD34+cells from the cord blood of ADA-deficient SCID neonates Nature Medicine 9 2003 463-468
34. Aiuti A. Slavin S. Aker M. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning Science 296 2002 2410-2413
35. Murray L. Luens K. Tushinski R. et al. Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture Human Gene Therapy 10 1999 1743-1752
36. Glimm H. Eaves C.J. Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture Blood 94 1999 2161-2168
37. Abonour R. Williams D.A. Einhorn L. et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells Nature Medicine 6 2000 652-658
38. Dunbar C.E. Takatoku M. Donahue R.E. The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model Annals of the New York Academy of Sciences 938 2001 236-244 discussion 244-235
39. Dando J.S. Aiuti A. Deola S. et al. Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+cells The Journal of Gene Medicine 3 2001 219-227
40. Williams D.A. Retroviral-fibronectin interactions in transduction of mammalian cells Annals of the New York Academy of Sciences 872 1999 109-113 discussion 113-104
41. Bolinger A.M. Zangwill A.B. Slattery J.T. et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease Bone Marrow Transplant 25 2000 925-930
42. Slavin S. Aker M. Shapira M.Y. et al. Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals Transfusion & Apheresis Science 27 2002 159-166
43. Huhn R.D. Tisdale J.F. Agricola B. et al. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning Human Gene Therapy 10 1999 1783-1790
44. Rosenzweig M. MacVittie T.J. Harper D. et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning Blood 94 1999 2271-2286
45. Aiuti A. Cattaneo F. Cassani B. et al. Safety and efficacy of stem cell gene therapy combined with nonmyeloablative conditioning for the treatment of ADA-SCID Blood 102 2003 531
46. Bonini C. Grez M. Traversari C. et al. Safety of retroviral gene marking with a truncated NGF receptor Nature Medicine 9 2003 367-369
47. Kohn D.B. Sadelain M. Dunbar C. et al. American Society of Gene Therapy (ASGT) Ad Hoc Subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells Molecular Therapy 8 2003 180-187
48. Hacein-Bey-Abina S. Von Kalle C. Schmidt M. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302 2003 415-419
49. Kohn D.B. Sadelain M. Glorioso J.C. Occurrence of leukaemia following gene therapy of X-linked SCID Nature Review Cancer 3 2003 477-488
50. Berns A. Good news for gene therapy New England Journal of Medicine 350 2004 1679-1680
51. Dave U.P. Jenkins N.A. Copeland N.G. Gene therapy insertional mutagenesis insights Science 303 2004 333
52. Cavazzana-Calvo M. Thrasher A. Mavilio F. The future of gene therapy Nature 427 2004 779-781
53. Candotti F. Podsakoff G. Schurman S. et al. Corrective gene transfer into bone marrow CD34+cells for adenosine deaminase (ADA) deficiency: results in four patients after one year of follow-up Molecular Therapy 7 2003 S448-S449
54. Cavazzana-Calvo M. Hacein B.S. de Saint Basile G. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Science 288 2000 669-672
55. Hacein-Bey-Abina S. Le Deist F. Carlier F. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy New England Journal of Medicine 346 2002 1185-1193
56. Fischer A. Landais P. Friedrich W. et al. European experience of bone-marrow transplantation for severe combined immunodeficiency Lancet 336 1990 850-854
57. Haddad E. Landais P. Friedrich W. et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients Blood 91 1998 3646-3653